Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons
Anis A Hamid, Michael J Morris, Ian D Davis
European Urology Focus | ELSEVIER | Published : 2019
Recent clinical trials have changed the treatment landscape for metastatic castration-sensitive prostate cancer. Ongoing and future studies using new therapeutic approaches hold the promise of further improving outcomes for patients with advanced prostate cancer.
Awarded by NHMRC Practitioner Fellowship
Anis A. Hamid is supported by a Prostate Cancer Foundation Young Investigator Award. Michael J. Morris is a recipient of a Movember GAP2 Award and Prostate Cancer Foundation Challenge Award. Ian D. Davis is supported by an NHMRC Practitioner Fellowship (APP1102604).